Post-earnings recap
Reported
Thu, Mar 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 7.87%. The management's focus on upcoming clinical data and maintaining a strong cash position suggests they are preparing for future growth opportunities. However, the lack of revenue details and guidance leaves some uncertainty for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.46 | N/A | +1.12% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their pipeline. They are focused on upcoming milestones that could impact future performance.
Management expressed confidence in their ongoing clinical trials.
They highlighted the importance of upcoming data releases for future growth.
There was an emphasis on maintaining a strong cash position.